Skip to main content
Figure 3 | Molecular Pain

Figure 3

From: PI3K mediated activation of GSK-3β reduces at-level primary afferent growth responses associated with excitotoxic spinal cord injury dysesthesias

Figure 3

GSK-3β is inhibited in the spinal dorsal horn and DRG 3 day following QUIS injection. Immunofluorescent staining of GSK-3βP in the spinal cord dorsal horn (top row) and DRG (bottom row) is increased 3 days following QUIS-induced SCI compared to sham vehicle treated controls; 3 days of LY294002 (LY) treatment significantly reduces GSK-3βP staining following QUIS-induced SCI. Quantification of GSK-3βP immunofluorescence intensity in SC (a) and DRG (b) (mean ± SEM. *p < 0.05. Scale bar 50 μm). Number of animals per group: sham vehicle (veh) n = 5, QUIS (veh) n = 5, QUIS (LY) n = 4.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us